Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 221 to 230 of 274 total matches.

Treatment of Clostridioides difficile Infection

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021  (Issue 1632)
, abdominal pain, and hypokalemia. Fidaxomicin is also poorly absorbed. It can cause nausea, vomiting ...
Clostridioides (formerly Clostridium) difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. Guidelines on management of CDI have recently been updated.
Med Lett Drugs Ther. 2021 Sep 6;63(1632):137-41 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
and epigastric pain. Hemolysis may occur in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
, vomiting, diarrhea, headache, and abdominal pain. Pancreatitis, hepatotoxicity, pericarditis, pneumonitis ...
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12   doi:10.58347/tml.2023.1680a |  Show IntroductionHide Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
It should not be used in patients taking an opioid for treatment of pain. Oral naltrexone should ...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44   doi:10.58347/tml.2023.1684a |  Show IntroductionHide Introduction

Drugs for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
pain, nausea, myalgia, injection-site reactions, influenza, neutropenia, and tinea infections ...
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60   doi:10.58347/tml.2024.1712a |  Show IntroductionHide Introduction

Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
common, which occurred in 1-7% of patients, were ocular hyperemia, instillation-site pain ...
A 0.24% ophthalmic solution of the second-generation H1-antihistamine cetirizine (Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine (Zyrtec, and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):81-3 |  Show IntroductionHide Introduction

Ofatumumab (Kesimpta) for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
reactions, headache, urinary tract infection, back pain, and decreased blood immunoglobulin M levels ...
The FDA has approved a subcutaneous formulation of the recombinant human anti-CD20 antibody ofatumumab (Kesimpta – Novartis) for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Kesimpta is the second anti-CD20 antibody to be approved for these indications; IV ocrelizumab (Ocrevus), which is also approved for treatment of primary progressive MS, was the first. An IV formulation of ofatumumab (Arzerra) has...
Med Lett Drugs Ther. 2020 Dec 28;62(1614):203-5 |  Show IntroductionHide Introduction

Inhaled Mannitol (Bronchitol) for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
, hemoptysis, and oropharyngeal pain occurred in 15.0%, 10.4%, and 7.0%, respectively, of adults treated ...
The FDA has approved mannitol powder for oral inhalation (Bronchitol – Chiesi) as add-on maintenance treatment to improve pulmonary function in adults with cystic fibrosis (CF). This product has been available in Europe for the same indication since 2012. Another formulation of mannitol inhalation powder (Aridol) is approved in the US for assessment of bronchial hyperresponsiveness.
Med Lett Drugs Ther. 2021 May 31;63(1625):85-6 |  Show IntroductionHide Introduction

Myfembree for Fibroid-Associated Heavy Menstrual Bleeding

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021  (Issue 1630)
treated with the combination had significant decreases in pain, distress from bleeding and pelvic ...
Myfembree (Myovant/Pfizer), an oral fixed-dose combination of the gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix, the estrogen estradiol, and the progestin norethindrone acetate, has been approved by the FDA for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. It is the second product to be approved in the US for this indication; Oriahnn, which contains the GnRH receptor antagonist elagolix in combination with estradiol and norethindrone acetate, was approved earlier. Relugolix was approved for...
Med Lett Drugs Ther. 2021 Aug 9;63(1630):121-3 |  Show IntroductionHide Introduction

Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021  (Issue 1634)
dyspepsia, dry mouth, abdominal pain, anxiety, nervousness, restlessness, agitation, irritability, tics ...
The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate (Azstarys – Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Azstarys is the first product containing serdexmethylphenidate to become available in the US.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):157-9 |  Show IntroductionHide Introduction